Evidence map›Paper›PMID 38740766›Full record

ArticleNature communications2024

Microfibril-associated glycoprotein 4 forms octamers that mediate interactions with elastogenic proteins and cells.

Michael R Wozny, Valentin Nelea, Iram Fatima S Siddiqui, Shaynah Wanga, Vivian de Waard, Mike Strauss, Dieter P Reinhardt

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael R Wozny *Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Valentin Nelea *Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Iram Fatima S SiddiquiFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
Shaynah WangaAmsterdam UMC location University of Amsterdam, Medical Biochemistry, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Vivian de WaardAmsterdam UMC location University of Amsterdam, Medical Biochemistry, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Mike StraussFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. mike.strauss@mcgill.ca.ORCID http://orcid.org/0000-0002-0986-2868
Dieter P ReinhardtFaculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. dieter.reinhardt@mcgill.ca.ORCID http://orcid.org/0000-0001-6535-9872

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) MFE-187851Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) PJT-186194Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) RGPIN-2020-04837Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Conseil de Recherches en Sciences Naturelles et en Génie du Canada) RGPIN-2022-05045
6 · The paper itself

Abstract

Microfibril-associated glycoprotein 4 (MFAP4) is a 36-kDa extracellular matrix glycoprotein with critical roles in organ fibrosis, chronic obstructive pulmonary disease, and cardiovascular disorders, including aortic aneurysms. MFAP4 multimerises and interacts with elastogenic proteins, including fibrillin-1 and tropoelastin, and with cells via integrins. Structural details of MFAP4 and its potential interfaces for these interactions are unknown. Here, we present a cryo-electron microscopy structure of human MFAP4. In the presence of calcium, MFAP4 assembles as an octamer, where two sets of homodimers constitute the top and bottom halves of each octamer. Each homodimer is linked together by an intermolecular disulphide bond. A C34S missense mutation prevents disulphide-bond formation between monomers but does not prevent octamer assembly. The atomic model, built into the 3.55 Å cryo-EM map, suggests that salt-bridge interactions mediate homodimer assembly, while non-polar residues form the interface between octamer halves. In the absence of calcium, an MFAP4 octamer dissociates into two tetramers. Binding studies with fibrillin-1, tropoelastin, LTBP4, and small fibulins show that MFAP4 has multiple surfaces for protein-protein interactions, most of which depend upon MFAP4 octamer assembly. The C34S mutation does not affect these protein interactions or cell interactions. MFAP4 assemblies with fibrillin-1 abrogate MFAP4 interactions with cells.

Indexed as

Cryoelectron MicroscopyExtracellular Matrix ProteinsFibrillin-1MicrofibrilsTropoelastinAdipokinesCalciumCarrier ProteinsGlycoproteinsHEK293 CellsHumansModels, MolecularMutation, MissenseProtein BindingProtein MultimerizationAdipokinesCalciumCarrier ProteinsExtracellular Matrix ProteinsFBN1 protein, humanFibrillin-1GlycoproteinsMFAP4 protein, humanTropoelastin

Identifiers

PMID38740766
PMCPMC11091212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.